Comment
. 2011 Feb;127(2):548; author reply 548-9.
doi: 10.1016/j.jaci.2010.10.055.
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy
- PMID: 21281877
- DOI: 10.1016/j.jaci.2010.10.055
Item in Clipboard
Comment
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy
J Allergy Clin Immunol.
2011 Feb.
No abstract available
Comment on
-
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.J Allergy Clin Immunol. 2010 Feb;125(2):383-9. doi: 10.1016/j.jaci.2009.11.022. J Allergy Clin Immunol. 2010. PMID: 20159249 Clinical Trial.
Similar articles
-
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.J Allergy Clin Immunol. 2010 Feb;125(2):383-9. doi: 10.1016/j.jaci.2009.11.022. J Allergy Clin Immunol. 2010. PMID: 20159249 Clinical Trial.
-
Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma.J Allergy Clin Immunol. 2011 Jan;127(1):286; author reply 286-7. doi: 10.1016/j.jaci.2010.07.033. Epub 2010 Sep 20. J Allergy Clin Immunol. 2011. PMID: 20850867 No abstract available.
-
Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma.J Allergy Clin Immunol. 2010 Jun;125(6):1220-7. doi: 10.1016/j.jaci.2010.02.034. J Allergy Clin Immunol. 2010. PMID: 20434204 Clinical Trial.
-
Anti-immunoglobulin E therapy with omalizumab for asthma.Ann Pharmacother. 2007 Sep;41(9):1397-410. doi: 10.1345/aph.1K005. Epub 2007 Aug 14. Ann Pharmacother. 2007. PMID: 17698897 Review.
-
An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.Allergy. 2008 Jun;63(6):670-84. doi: 10.1111/j.1398-9995.2008.01723.x. Allergy. 2008. PMID: 18445184 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
